Evidence-Based Summary
CJC-1295 and tesamorelin are both synthetic peptide analogues of human growth hormone-releasing hormone (GHRH) designed to stimulate pituitary somatotrophs to release endogenous growth hormone (GH), but their chemical engineering, clinical validation, and regulatory realities are worlds apart. Tesamorelin (Egrifta) is a 44-amino-acid peptide identical to human GHRH(1-44) with the addition of a trans-3-hexenoyl group at the N-terminus that protects it from enzymatic degradation by DPP-4. Approved by the FDA in 2010 (NDA 022505), tesamorelin preserves normal physiological pulsatile GH release, stimulates hepatic IGF-1, and demonstrated significant reductions in visceral adipose tissue in rigorous Phase 3 clinical trials. In contrast, CJC-1295 is a modified 29-amino-acid fragment (mod GRF 1-29) engineered with a maleimidoproprionic acid linker (the Drug Affinity Complex, or DAC) that forms an irreversible covalent bond with circulating human serum albumin. This extends its half-life from minutes to 6–8 days, causing continuous, non-pulsatile GHRH receptor stimulation. CJC-1295 is NOT approved by the FDA or EMA. Its Phase 2 clinical trials were permanently halted following a fatal coronary event in a trial participant, and it is explicitly prohibited in athletic competition by the World Anti-Doping Agency (WADA Section S2).
Quick Comparison: CJC-1295 vs Tesamorelin
A high-level comparison of molecule class, molecular receptor targets, FDA regulatory approvals, and verified clinical programs.
| Feature | CJC-1295 | Tesamorelin |
|---|---|---|
| Primary classification | Synthetic GHRH analogue with DAC (Unapproved) | Synthetic GHRH analogue (FDA-approved medicine) |
| Peptide structure | 29-amino-acid core + maleimidoproprionic linker | 44-amino-acid sequence + trans-3-hexenoyl N-cap |
| Albumin binding chemistry | Covalent irreversible bond to albumin via Cys34 | Non-covalent standard biological distribution |
| Elimination half-life | ~6 to 8 days (with DAC) | ~26 to 38 minutes |
| GH secretion dynamics | Continuous, non-physiological elevated baseline | Preserves natural episodic pulsatile GH spikes |
| FDA regulatory status | Unapproved investigational compound (Clinical hold) | FDA-approved prescription drug (NDA 022505, Egrifta) |
| Approved clinical indication | None (Development discontinued) | Reduction of excess visceral abdominal fat in HIV lipodystrophy |
| WADA prohibited status | Prohibited at all times (Section S2: Peptide Hormones) | Prohibited at all times (Section S2: Peptide Hormones) |
Continuous Receptor Occupancy vs Pulsatile Stimulation
Both peptides bind the GHRH receptor on anterior pituitary somatotrophs, but their kinetics produce vastly different endocrine profiles.
CJC-1295: Non-Pulsatile Somatotroph Stimulation
Primary Target: Growth Hormone-Releasing Hormone Receptor (GHRHR)
Affinity Profile: High affinity for GHRHR; persistent receptor binding
Formulated with the DAC technology, CJC-1295 binds covalently to circulating albumin within minutes of subcutaneous injection. Because albumin has a half-life of 20 days, somatotroph GHRH receptors are exposed to continuous, non-pulsatile stimulation, elevating baseline trough GH levels and raising IGF-1 for 1 to 2 weeks per dose. However, continuous stimulation risks somatotroph desensitization.
Tesamorelin: Preservation of Physiological GH Pulsatility
Primary Targets: Growth Hormone-Releasing Hormone Receptor (GHRHR)
Affinity Profile: Native-like high affinity for pituitary GHRHR
Tesamorelin's hexenoyl group resists DPP-4 cleavage, extending its bioactivity sufficiently to trigger somatotroph depolarization while clearing within hours. This stimulates discrete physiological growth hormone secretory pulses that stimulate hepatic IGF-1 synthesis and drive lipolysis in visceral fat without abolishing endogenous somatostatin negative feedback.
FDA Approval vs Terminated Clinical Development
The regulatory trajectories of these two molecules could not be more divergent.
CJC-1295 Status & Formulations
Not approved by the FDA or EMA for human clinical use.
Tesamorelin Status & Formulations
Egrifta / Egrifta SV (Tesamorelin)
Approval History: 2010 (Original); 2019 (Concentrated SV formulation) (NDA 022505 / 214797)
Approved Indications: Reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Critical Regulatory Distinction
Phase 2 clinical development of CJC-1295 DAC was permanently halted by the sponsor (ConjuChem) in 2006 following the death of a patient from a myocardial infarction during a trial. Tesamorelin completed Phase 3 trials in over 800 patients demonstrating efficacy and cardiovascular safety.
Phase 3 Registrational Data vs Terminated Phase 2 Trials
Evaluating the human evidence base for both GHRH analogues.
CJC-1295: CJC-1295 Early Clinical Data
In early Phase 1/2 healthy volunteer studies (Teichman et al., J Clin Endocrinol Metab 2006), CJC-1295 DAC increased mean plasma GH levels by 2- to 10-fold and sustained IGF-1 elevation for up to 14 days following a single dose. However, registrational development was terminated in 2006 due to severe safety signals.
Tesamorelin: Tesamorelin Phase 3 Evidence
Two randomized, double-blind, multicenter Phase 3 trials (Falutz et al., NEJM 2007; J Clin Endocrinol Metab 2010) demonstrated that tesamorelin 2 mg daily significantly reduced visceral adipose tissue by 15% to 18% at 26 weeks, reduced waist circumference, and improved lipid parameters without altering glucose tolerance.
Safety Warning & Clinical Risks
Elevating systemic GH and IGF-1 carries known endocrine and metabolic risks.
| Safety Consideration | CJC-1295 | Tesamorelin |
|---|---|---|
| Clinical trial safety record | Phase 2 trial halted due to fatal coronary event | Extensive safety database in >800 clinical trial participants |
| Injection site reactions | Pain, erythema, induration | Erythema, pruritus, pain (reported in ~25-35% of patients) |
| Arthralgias and peripheral edema | Common due to sustained fluid retention | Observed in ~10-15% of patients (dose-dependent GH effect) |
| Glucose tolerance impact | Elevated fasting glucose observed in trials | Transient slight increase in HbA1c; monitor diabetic patients |
| Neoplasm risk | Theoretical risk from sustained high IGF-1 | Contraindicated in active malignancy; requires screening |
What CJC-1295 and Tesamorelin Have in Common
Where the two compounds overlap in biology, evidence or regulatory context.
GHRH Receptor Target
Both peptides target the GHRH receptor on anterior pituitary somatotrophs to stimulate endogenous GH.
IGF-1 Elevation
Both molecules stimulate hepatic synthesis and secretion of insulin-like growth factor-1 (IGF-1).
WADA Prohibition
Both substances are banned at all times in competitive sports under WADA Section S2.
Key Scientific & Clinical Differences
Meaningful distinctions in mechanism, strength of evidence, safety and regulatory status.
FDA Regulatory Approval
Tesamorelin is FDA approved (Egrifta); CJC-1295 is an unapproved chemical whose trials were discontinued.
GH Pulsatility Preservation
Tesamorelin preserves natural episodic GH pulses; CJC-1295 DAC forces continuous non-pulsatile elevation.
Evidence for Visceral Fat Loss
Tesamorelin is clinically proven to reduce visceral adipose tissue in Phase 3 RCTs; CJC-1295 lacks controlled obesity trials.
Scientific Comparison vs Clinical Recommendations
Inside Peptides compares scientific evidence, receptor pharmacology, and official regulatory documents to advance public and professional understanding. We do not determine which compound is appropriate for an individual patient, rank medications with arbitrary scores, or recommend initiating or switching treatments.
Decisions about any medicine require a licensed healthcare professional who can weigh personal medical history, contraindications, interactions and monitoring needs. Unapproved peptides have no established safe use, and products sold as “research chemicals” are not the preparations studied in clinical research.
Approved Uses vs Online Claims
A critical scientific distinction between verified, FDA-approved clinical uses and unverified claims circulating on social media and vendor platforms.
CJC-1295 is just an affordable generic version of Tesamorelin
insufficientCJC-1295 is NOT a generic version of tesamorelin; they are different chemical entities with different safety histories.
CJC-1295 has a different sequence length (29 aa vs 44 aa), different modifications (DAC albumin linker vs hexenoyl cap), and failed clinical development due to cardiovascular safety concerns.
Evidence Strength Across Clinical Domains
Inside Peptides evaluates scientific certainty at the claim level. Because clinical evidence varies significantly depending on the therapeutic endpoint evaluated, each domain is assessed independently.
Endogenous GH/IGF-1 Elevation
Both reliably elevate GH and IGF-1 in clinical studies.
Visceral Adipose Tissue Reduction
Tesamorelin validated in Phase 3 trials; CJC-1295 lacks Phase 3 efficacy data.
Human Clinical Safety
Tesamorelin has established safety labeling; CJC-1295 was halted after fatal adverse event.
What Research Still Doesn’t Tell Us
Identifying open scientific questions, pending active-comparator trials, and areas where long-term clinical data remain incomplete.
Tesamorelin in Non-HIV NAFLD/MASH
Investigating tesamorelin's efficacy in non-alcoholic fatty liver disease in non-HIV populations.
Related Compound Profiles
Individual profiles provide full molecular datasheets, CAS numbers, preclinical histories, and compound monographs.
Related Educational Resources
Scientific & Regulatory References
Every pharmacological mechanism, clinical trial result, and regulatory approval cited on this page is traceable to official FDA prescribing documentation, ClinicalTrials.gov registries, or peer-reviewed medical publications.
-
Peer-Reviewed RCT
Metabolic effects of a growth hormone-releasing factor in patients with HIV
-
Clinical Pharmacology
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone